Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Dr Golant on Atopic Dermatitis (October 2026)

How does targeting JAK-STAT signaling in the skin translate into the clinical effects seen with ruxolitinib cream in AD?
Oct 20, 2026Atopic Dermatitis

How does targeting JAK-STAT signaling in the skin translate into the clinical effects seen with ruxolitinib cream in AD?

-

What have you learned about setting expectations for ruxolitinib cream that helps patients use it appropriately in real-world practice?
Oct 20, 2026Atopic Dermatitis

What have you learned about setting expectations for ruxolitinib cream that helps patients use it appropriately in real-world practice?

-

Where does ruxolitinib cream fit for patients who have relied on repeated courses of topical corticosteroids to manage their AD?
Oct 20, 2026Atopic Dermatitis

Where does ruxolitinib cream fit for patients who have relied on repeated courses of topical corticosteroids to manage their AD?

-

Where does ruxolitinib cream fit into your current approach to topical treatment for AD?
Oct 20, 2026Atopic Dermatitis

Where does ruxolitinib cream fit into your current approach to topical treatment for AD?

-

What does moderate AD look like in real-world practice, and what can make its severity easy to underestimate?
Oct 20, 2026Atopic Dermatitis

What does moderate AD look like in real-world practice, and what can make its severity easy to underestimate?

-

How do you determine the role of steroidal and nonsteroidal topical therapies within a longer-term treatment plan?
Oct 20, 2026Atopic Dermatitis

How do you determine the role of steroidal and nonsteroidal topical therapies within a longer-term treatment plan?

-